The acquisition brings Lilly a novel in vivo cell therapy platform built around engineered circular RNA and proprietary lipid nanoparticles
Motorica India conducted a specialised masterclass led by Shumaev, centred on real-life rehabilitation scenarios and personalised therapy programs before and after prosthetic fitting
The new OMR facility, located in Chennai’s medical hub, is close to leading hospitals and offers excellent road and air connectivity
Revenue from operations surged 30% year-on-year to Rs. 68,645 million
The unveiling marks Time Medical India’s entry into next-generation helium-free MRI technology
Semaglutide—a glucagon?like peptide?1 receptor agonist (GLP-1RA) sold as Ozempic and Rybelsus for type 2 diabetes, and Wegovy for weight management and cardiovascular risk reduction
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
LIVMARLI’s new tablet form offers patients weighing 22 kg or more a convenient, one-tablet-per-dose option, complementing the existing 9.5 mg/ml oral solution
The therapy is currently completing Phase 1 clinical trials in renal cell carcinoma and non-small cell lung cancer
Call it one of the most striking turnarounds in the Indian pharma sector this fiscal year
Subscribe To Our Newsletter & Stay Updated
